- Home
- RIGL
as 11-08-2024 3:39pm EST
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's lead drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.
| Founded: | 1996 | Country: | United States |
| Employees: | N/A | City: | SOUTH SAN FRANCISCO |
| Market Cap: | 247.1M | IPO Year: | 2000 |
| Target Price: | $31.13 | AVG Volume (30 days): | 103.3K |
| Analyst Decision: | Buy | Number of Analysts: | 4 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.81 | EPS Growth: | N/A |
| 52 Week Low/High: | $7.48 - $17.30 | Next Earning Date: | 11-07-2024 |
| Revenue: | $130,201,000 | Revenue Growth: | 7.48% |
| Revenue Growth (this year): | 38.26% | Revenue Growth (next year): | 24.21% |
Latest Rigel Pharmaceuticals Inc. News
RIGL Breaking Stock News: Dive into RIGL Ticker-Specific Updates for Smart Investing
Thomson Reuters StreetEvents
6 hours ago
Q3 2024 Rigel Pharmaceuticals Inc Earnings Call
GuruFocus.com
13 hours ago
Rigel Pharmaceuticals Inc (RIGL) Q3 2024 Earnings Call Highlights: Strong Sales Growth and ...
Zacks
a day ago
Rigel Pharmaceuticals (RIGL) Q3 Earnings and Revenues Top Estimates
Associated Press Finance
a day ago
Rigel: Q3 Earnings Snapshot
PR Newswire
a day ago
Rigel Reports Third Quarter 2024 Financial Results and Provides Business Update
GuruFocus.com
2 days ago
Rigel Pharmaceuticals Inc (RIGL) Q3 2024 Earnings Report Preview: What To Expect
PR Newswire
3 days ago
Rigel Announces Six Poster Presentations at the 66th American Society of Hematology Annual Meeting and Exposition
PR Newswire
8 days ago
Rigel Announces Conference Call and Webcast to Report Third Quarter 2024 Financial Results and Business Update
Compare RIGL vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "RIGL Rigel Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.